Summit's Lead Antimicrobial Fails Pivotal Study, May Spark Therapeutic Shift
Stock Down 50%
Ridinilazole fell short of significance in a late-stage trial, with some analysts now anticipating the company will alter its therapeutic strategy entirely.
Ridinilazole fell short of significance in a late-stage trial, with some analysts now anticipating the company will alter its therapeutic strategy entirely.